These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11022715)

  • 1. [Usefulness and problems of antiandrogen].
    Ozono S; Hirao Y
    Nihon Rinsho; 2000 Jul; 58 Suppl():206-10. PubMed ID: 11022715
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the role of antiandrogen therapy in the treatment of prostate cancer?
    Payne H
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S1-6. PubMed ID: 16896885
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostatic carcinoma treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan).
    Krarup T; Rasmussen F; Gammelgaard PA
    Scand J Urol Nephrol; 1978; 12(1):11-5. PubMed ID: 345431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the side effects of androgen-deprivation therapy.
    J Support Oncol; 2007 Feb; 5(2):87-8. PubMed ID: 17348368
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antiandrogen].
    Imamoto T; Kawamura K; Ichikawa T
    Nihon Rinsho; 2016 May; 74 Suppl 3():573-7. PubMed ID: 27344796
    [No Abstract]   [Full Text] [Related]  

  • 7. Reasons against total androgen suppression.
    Robinson MR
    Prog Clin Biol Res; 1990; 359():117-24; discussion 141-53. PubMed ID: 2284287
    [No Abstract]   [Full Text] [Related]  

  • 8. Differences in action and toxicity of antiandrogens.
    Neumann F; Bormacher K; Radlmaier A
    Prog Clin Biol Res; 1989; 303():123-8. PubMed ID: 2674981
    [No Abstract]   [Full Text] [Related]  

  • 9. Stage D1 prostate cancer--delayed androgen deprivation.
    Richie JP
    Urology; 1997 Dec; 50(6):838-9. PubMed ID: 9426710
    [No Abstract]   [Full Text] [Related]  

  • 10. [Osteoporosis due to androgen suppression therapy in men with prostate cancer].
    Roux C
    Prog Urol; 2003 Apr; 13(2 Suppl 1):24-7. PubMed ID: 12815806
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chemotherapy in hormone refractory prostatic carcinoma].
    Biedermann B; Pless M; Herrmann R
    Dtsch Med Wochenschr; 1999 Jul; 124(28-29):874-9. PubMed ID: 10432951
    [No Abstract]   [Full Text] [Related]  

  • 12. Is NNT AOK?
    Lee WR
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):640-1. PubMed ID: 15708240
    [No Abstract]   [Full Text] [Related]  

  • 13. Maximal androgen blockade (MAB) for the treatment of prostate cancer.
    Kirby RS
    Br J Clin Pract; 1996; 50(5):287. PubMed ID: 8794610
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
    Pitts WR
    BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
    [No Abstract]   [Full Text] [Related]  

  • 15. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of a benzopyran-containing androgen receptor antagonist to treat antiandrogen-resistant prostate cancer.
    Oh S; Nam HJ; Park J; Beak SH; Park SB
    ChemMedChem; 2010 Apr; 5(4):529-33. PubMed ID: 20135667
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
    Akaza H
    Cancer Sci; 2011 Jan; 102(1):51-6. PubMed ID: 21091846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis for the antiandrogen withdrawal syndrome.
    Miyamoto H; Rahman MM; Chang C
    J Cell Biochem; 2004 Jan; 91(1):3-12. PubMed ID: 14689576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer drugs. Making sense of the options.
    Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular implications of the antiandrogen withdrawal syndrome.
    Moul JW; Srivastava S; McLeod DG
    Semin Urol; 1995 May; 13(2):157-63. PubMed ID: 7543690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.